Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: A clinically useful risk stratification tool

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4581-4588

  Moore, Carol L ^a,b   Lu, Mei ^b   Cheema, Faiqa ^a   Osaki Kiyan, Paola ^a   Perri, Mary Beth ^a   Donabedian, Susan ^a   Haque, Nadia Z ^a,b   Zervos, Marcus J ^a,c  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGED; APACHE; ARTICLE; BLOODSTREAM INFECTION; CLASSIFICATION AND REGRESSION TREE ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION RISK; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT FAILURE; UNITED STATES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK ASSESSMENT; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN;

EID: 80052824523     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00115-11     Document Type: Article

References (37)

1. Ariano, R. E., A. Fine, D. S. Sitar, S. Rexrode, and S. A. Zelenitsky. 2005. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am. J. Kidney Dis. 46:681-687.
2. Breiman, L. 1984. Classification and regression trees. Wadsworth International Group, Belmont, CA.
3. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
4. Chua, T., et al. 2008. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J. Clin. Microbiol. 46:2345-2352.
5. CLSI. 2005. Performance standards for antimicrobial susceptibility testing: 15th informational supplement, document M100-S15. CLSI, Wayne, PA.
6. CLSI. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI, Wayne, PA.
7. Fowler, V. G., Jr., et al. 1999. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin. Infect. Dis. 28:106-114.
8. Frankel, M. R., et al. 2000. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 55:952-959.
9. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
10. Horan, T., and, G. R. P. 2004. Surveillance of nosocomial infections, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, PA.
11. Hsu, D. I., et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
12. Jeffres, M. N., W. Isakow, J. A. Doherty, S. T. Micek, and M. H. Kollef. 2007. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 29:1107-1115.
13. Karam, C. M., P. S. McKinnon, M. M. Neuhauser, and M. J. Rybak. 1999. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 19:257-266.
14. Klevens, R., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
15. Klevens, R. M., et al. 2006. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg. Infect. Dis. 12:1991-1993.
16. Kullar, R., S. L. Davis, D. P. Levine, and M. J. Rybak. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
17. Lina, G., et al. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132.
18. Lodise, T., P. McKinnon, L. Swiderski, and M. Rybak. 2003. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36:1418-1423.
19. Lodise, T. P., B. Lomaestro, J. Graves, and G. L. Drusano. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336.
20. Lodise, T. P., N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
21. McDougal, L., et al. 2003. Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
22. McDougal, L. K., et al. 2010. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob. Agents Chemother. 54:3804-3811.
23. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
24. Moise-Broder, P., et al. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705.
25. Moore, C., et al. 2009. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int. J. Antimicrob. Agents 34:148-155.
26. Moore, C., et al. 2009. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland, May 2009, abstr. P-1861.
27. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A. NCCLS, Wayne, PA.
28. Rybak, M. J., et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
29. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
30. Sakoulas, G., et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
31. Soriano, A., et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
32. Strommenger, B., C. Cuny, G. Werner, and W. Witte. 2004. Obvious lack of association between dynamics of epidemic methicillin-resistant Staphylococcus aureus in central Europe and agr specificity groups. Eur. J. Clin. Microbiol. Infect. Dis. 23:15-19.
33. Tenover, F. C., and R. V. Goering. 2009. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J. Antimicrob. Chemother. 64:441-446.
34. Wisplinghoff, H., et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
35. Wootton, M., A. MacGowan, T. Walsh, and R. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
36. Zhang, H., and B. Singer. 1999. Recursive partitioning in the health sciences. Springer, New York, NY.
37. Zhang, K., J. McClure, S. Elsayed, T. Louie, and J. Conly. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5026-5033.